
The following is an extract from the “Iveco Group 2026 First Quarter Results” press release(*). The complete press release can be accessed by visiting the media section of the Iveco Group corporate website: https://www.ivecogroup.com/media/corporate_press_releases or consulting the accompanying PDF:
A quarter focused on quality improvements against a backdrop of industrial volatility.
Defence sale completed in the quarter.
Tata Motors Tender Offer expected to close by Q3 2026.
Consolidated revenues amounted to €2,828 million compared to €2,806 million in Q1 2025. Net revenues of Industrial Activities were €2,766 million compared to €2,736 million in Q1 2025, mainly due to higher volumes in Bus, partially offset by negative volume in Truck in South America and an adverse foreign exchange rate impact.
Adjusted EBIT loss was €55 million compared to an Adjusted EBIT of €117 million in Q1 2025, with a negative margin of 1.9% (positive 4.2% in Q1 2025). Adjusted EBIT loss of Industrial Activities was €90 million (€82 million profit in Q1 2025), mainly driven by unfavorable production costs due to strengthened quality focus across businesses and rework costs in Bus. Adjusted EBIT margin of Industrial Activities was negative 3.3% (positive 3.0% in Q1 2025).
Adjusted net loss was €74 million compared to an adjusted net income of €60 million in Q1 2025, and adjusted diluted earnings per share was a loss of €0.28 (adjusted diluted earnings per share of €0.22 in Q1 2025). Q1 2026 Adjusted net loss did not include the net gain of €1,254 million on the sale of Defence business, included in the profit from Discontinued Operations, net of tax.
Net financial expenses amounted to €43 million compared to €37 million in Q1 2025 due to lower interest income in Türkiye and Brazil.
Reported income tax benefit of €36 million, deriving from a loss before taxes of €152 million, with an adjusted Effective Tax Rate (adjusted ETR) of 24% in Q1 2026, which reflects the different tax rates applied in the jurisdictions where the Group operates and some other discrete items.
Free cash flow of Industrial Activities was negative at €681 million compared to negative €847 million in Q1 2025, mainly driven by lower working capital absorption.
Available liquidity was €5,498 million as of 31st March 2026, before the extraordinary interim dividend distribution of €1,551 million, occurred on 22nd April 2026, on the net proceeds from the sale of Defence business. Available liquidity also included €1,900 million of undrawn committed facilities.
(*) 2026 and 2025 financial data shown refer to Continuing Operations only (ie. excluding Defence business), unless otherwise stated. In particular, on 18th March 2026, Iveco Group transferred the full ownership of its Defence business (IDV and ASTRA brands) to Leonardo S.p.A., as per the terms of the agreement announced on 30th July 2025. Following the signing of that agreement, the Defence business has been classified as Discontinued Operations.
Attachment
-
Honda携海陆空全领域产品亮相北京车展2026年4月24日,第十九届北京国际汽车展览会(以下简称:北京车展)正式开幕。本田技研工业(中国)投资有限公司(以下简称:Honda)联合广汽本田汽车有限公司(以下简称:2026-05-07
-
Honda携海陆空全领域产品亮相北京车展2026年4月24日,第十九届北京国际汽车展览会(以下简称:北京车展)正式开幕。本田技研工业(中国)投资有限公司(以下简称:Honda)联合广汽本田汽车有限公司(以下简称:2026-05-07
-
正雅齿科智利首场学术会议圆满落幕 深化南美市场数字化正畸布局上海2026年5月7日 美通社 -- 正雅在智利举办的首场大型学术会议于4月27日顺利落下帷幕。本次会议不仅是正雅正式进入智利市场的里程碑,更标志着其服务南美隐形正畸2026-05-07
-
Iveco Group 2026 First Quarter ResultsThe following is an extract from the “Iveco Group 2026 First Quarter Results” press release(*). The complete press release can be accessed by visi2026-05-07
-
金赛药业伏欣奇拜单抗水剂获批上市,使用更便利,半年降低痛风复发风险近90%上海2026年5月7日 美通社 -- 近日,长春金赛药业有限责任公司(以下简称“金赛药业”)自主研发的伏欣奇拜单抗注射液(水剂)正式获得国家药品监督管理局核准签发的《药品注2026-05-07
-
AMD股价暴跌17%创近9年之最,苏姿丰紧急回应:AI增速远超想象
-
江苏省脑机接口产业联盟在宁成立,麦澜德分享前沿成果
-
艾芬达入选国家知识产权强国建设示范创建对象:二十载长期主义,兑现每一份用户价值
-
慧启赣疆 聚势共赢丨慧友酒店集团江西品鉴会书写区域文旅融合新篇
-
电影《一秒》定档:2026年,活在这一秒
-
西藏斜视患儿寒假进京手术成功,千里护航点亮视觉未来
-
年度盛典|卓兴半导体2025年度总结表彰暨 2026 年迎新晚会
-
倒计时21天!2026未来医疗医药100强大会议程再刷新
-
科技赋能 生态协同,登途集团车辆资产管理运营模式助推行业提质增效
-
公元地暖构建“产品+施工+服务”全维保障网,兑现50年温暖承诺
